June 1, 2009
May 31, 2010
This activity was originally presented as a LIVE symposium in Jacksonville, Florida on April 20, 2009 at the College of Psychiatric and Neurologic Pharmacists (CPNP) 2009 Annual Meeting. If you attended this symposium, you are not able to receive credit for the online version, but you are welcome to use it as a resource in your practice.
This web-based activity will feature a diverse panel of psychiatric pharmacy clinicians discussing medication adherence and continuity of care in the schizophrenia patient who transitions through the health care system and demonstrates nonadherence with therapy. Presentations will be case-based and utilize audience response testing to provide interactive learning for participants.
Psychiatric pharmacists and related health care professionals who manage treatment regimens in the seriously mentally ill.
- Welcome and Introductions
- Presentation and Clinical Case Discussion
- Posttest and Evaluation
At the conclusion of this application-based activity, participants will be able to:
- Recognize the economic, emotional, and physical impact among patients with schizophrenia who demonstrate poor medication-taking behavior.
- Manage the pharmacologic treatment of patients with schizophrenia to improve antipsychotic medication adherence through the use of innovative treatment strategies and dosage forms.
- Implement nonpharmacologic strategies to improve medication-taking behaviors in patients with schizophrenia.
- Recognize systems-level barriers that may hinder delivery of ideal pharmacologic and nonpharmacologic treatment in patients with schizophrenia.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in educational presentations. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
 |
Jonathan P. Lacro, PharmD, BCPS, BCPP (Moderator/Chair)
Clinical Pharmacy Specialist in Psychiatry
Director of Pharmacy Education and Training
VA San Diego Healthcare System
Associate Clinical Professor of Psychiatry
University of California, San Diego
San Diego, CA
Dr. Lacro is Director of Pharmacy Education and Training at the VA San Diego Healthcare System. Specifically, he serves as the Program Director for their PGY1 Pharmacy Practice and PGY2 Psychiatric Pharmacy Practice Residency programs. He also serves as Director of Clinical Specialists in Pharmacy and is a Clinical Pharmacy Specialist in Psychiatry. He is a Research Scientist for the Veterans Medical Research Foundation and Associate Clinical Professor of Psychiatry and Pharmacy at the University of California, San Diego. He is also a Fellow of the California Society of Health-System Pharmacists and the American Society of Health-System Pharmacists and is Board Certified as a Pharmacotherapy Specialist and a Psychiatric Pharmacist.
Dr. Lacro earned his Doctor of Pharmacy Degree from the University of the Pacific School of Pharmacy in Stockton, California. After graduating, he completed a pharmacy practice residency at the VA San Diego and a fellowship at the University of California, San Diego with an emphasis in geriatric psychiatry.
Dr. Lacro's clinical and research interests are primarily devoted to schizophrenia and other psychotic disorders, geriatric psychiatry and the optimal use of psychopharmacologic therapies. His clinical responsibilities include providing medication management services in a Cognitive Disorders Clinic and a Geriatric Psychiatry Clinic. Dr. Lacro has been actively involved in psychopharmacology studies since 1991. Currently, he is the Principal Investigator of an NIMH-supported grant on "Medication Adherence Therapy in Older Psychotic People" and is a co-investigator of the NIMH-funded Geriatric Psychiatry Center for Community-Based Research in Older People with Psychoses at UCSD. He has previously received federal funding for projects titled "Antipsychotic Treatment in Late-Life Schizophrenia" and "Exploring the Rationality of Co-Medication in Antipsychotic Treatment." He is the author or coauthor of articles published in journals such as Journal of Clinical Psychiatry, American Journal of Psychiatry, Journal of Clinical Psychopharmacology and Journal of the American Geriatrics Society.
Dr. Lacro has disclosed that he is a consultant for Lilly and receives grant/research support from the National Institute of Mental Health.
|
 |
Kelly N. Gable, PharmD, BCPP
Assistant Professor, Dept. of Pharmacy Practice
Southern Illinois University Edwardsville School of Pharmacy
Edwardsville, IL
Psychiatric Clinical Pharmacist
Community Alternatives
St. Louis, MO
Dr. Gable is Assistant Professor in the Department of Pharmacy Practice at SIUE School of Pharmacy in Edwardsville, IL. Dr. Gable is a graduate of the University of Mississippi School of Pharmacy, and subsequently completed a specialty residency in Psychiatric Pharmacy Practice at the University of Southern California. She is a Board Certified Psychiatric Pharmacist and currently holds a joint appointment with the Saint Louis University School of Medicine, Department of Neurology and Psychiatry. Her clinical appointment is with Community Alternatives, a mental health outreach clinic in St. Louis, Missouri where she works collaboratively with psychiatry to provide care to underprivileged clients with severe and persistent mental illnesses. She has integrated her pharmacy services into Assertive Community Treatment (ACT), a community-based, recovery focused, multidisciplinary team approach to treating mental illness.
Dr. Gable has nothing to disclose.
|
 |
Eric C. Kutscher, PharmD, BCPP
Associate Professor, Dept. of Pharmacy Practice
South Dakota State University College of Pharmacy
Clinical Pharmacy Specialist, Psychiatry
Avera Behavioral Health Center
Sioux Falls, SD
Dr. Kutscher is Associate Professor of Pharmacy Practice at South Dakota State University and Assistant Professor of Psychiatry at the Sanford-USD School of Medicine. Dr. Kutscher is a Board Certified Psychiatric Pharmacist and has a practice site at the Avera Behavioral Health Center in Sioux Falls, SD. He provides consultative services in the areas of psychopharmacology, forensic pharmacology and substance abuse. He has published over 15 peer reviewed papers, has authored and edited a variety of book chapters and serves as an editor for many major psychiatric and pharmacy journals. Dr. Kutscher is a former board member of NAMI-SD and is currently the President of the South Dakota Society of Health-System Pharmacists. Dr. Kutscher is actively involved with national organizations and has presented on a variety of topics on a national scale, specifically he provides research review and mentorship for the College of Psychiatric and Neurologic Pharmacists and the American Society of Health-System Pharmacists.
Dr. Kutscher has nothing to disclose.
|
 |
Christopher J. Thomas, PharmD, BCPP, BCPS, CGP
Clinical Pharmacy Specialist in Psychiatry
Veterans Affairs Medical Center
Chillicothe, OH
Assistant Professor of Pharmacology
Ohio University College of Osteopathic Medicine
Athens, OH
Dr. Thomas is the Clinical Pharmacy Specialist in Psychiatry and Residency Program Director of the PGY1 residency at the Chillicothe VAMC. He is also Assistant Professor of Pharmacology at Ohio University College of Osteopathic Medicine.
Board Certified in Psychiatry, psychopharmacology, and Geriatrics, Dr. Thomas completed his Doctor of Pharmacy Degree at Butler University in Indianapolis, IN. He completed a specialty pharmacy practice residency in psychopharmacology/psychiatric pharmacy practice at the Cleveland VAMC from 2000 to 2001.
He is an active member in the College of Psychiatric and Neurologic Pharmacists, American Society of Consultant Pharmacists, American Society of Health-System Pharmacists and the American College of Clinical Pharmacy. In 2003, he was recognized as a Fellow of the American Society of Consultant Pharmacists.
Dr. Thomas' research interests and publications involve catatonia and the role of glutamate, the role of norepinephrine and glutamate in agitation, aggression, and anxiety disorders and the metabolic adverse events with the second-generation antipsychotics.
Dr. Thomas has disclosed that he is a consultant for AstraZeneca; receives grant/research support from Pfizer; and is a member of the Speakers' Bureaus for Abbott, AstraZeneca, and Pfizer.
|
The planners and managers have no financial or other relationship to products or devices with commercial interests related to the content of this CPE activity.
 |
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of
continuing pharmacy education. This activity has been assigned ACPE# 245 000-09-021-H01-P and will award 1.5 contact hours (.15 CEUs)
of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming. Statements
of credit will be issued immediately upon successful completion of an online posttest and evaluation.
|
To receive a statement of credit, you must:
- Review the full content of the activity and reflect upon its teachings
- Complete the questions and evaluation at the end of the activity
Statements of credit will be immediately available online for all healthcare professionals who successfully complete the activity and evaluation.
Please click here to download a PDF of the PowerPoint slides for your reference.
This activity is complimentary.
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
|
This activity was supported by an educational grant from Janssen
|
|
|
administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
|
|
|
 |
